Saatchi shop uses rebrand to refocus

Share this article:
Saatchi shop uses rebrand to refocus
Saatchi shop uses rebrand to refocus

Saatchi & Saatchi Innovations, Publicis' Pennsylvania-based outpost servicing specialty pharma, is rebranding as Saatchi Science.

The Yardley, PA-based shop is looking to sharpen its brand with the name change.

"It's really a reflection of our ‘Go Forward' business strategy,” said the shop's managing director,  Anne­marie Armstrong. “We're narrowing our focus to broaden our appeal to very specific clients in high science and highly complex categories, like oncology, molecular diagnostics and immunology and vaccines. We wanted an identity that reflects that.”

In addition to the new name, the 65-person shop is investing in analytics capability for oncology. Saatchi Science clients include: Pfizer, for which the firm works on Torisel; AstraZeneca, for Caprelsa and Faslodex; and Sanofi Pasteur, for the vaccines portfolio (both adult and pediatric).

“We're building from our strengths,” said Armstrong. “We believe these categories, particularly oncology and molecular diagnostics in the era of personalized medicine, are very different than [small molecule therapies], so we're investing in the right mix of marketing strategy, scientific understanding, customer insights and creative communications so that we're focusing all of our resources to deliver for these clients.”

Armstrong was named managing director of the shop in July, having previously served in that role on an interim basis. Previously based in Newton, PA, the agency moved in with Publicis Healthcare Communications Group siblings Publicis Touchpoint Solutions and Publicis HealthWare International last year.

The Saatchi healthcare franchise also includes New York-based Saatchi Wellness, which specializes in consumer and patient communications, and Saatchi & Saatchi Health Communications, the network's mainline professional-focused arm.
Share this article:

Email Newsletters

More in Features

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.